Sarepta pays $500M cash for rights to 'multiple potential blockbusters' from Arrowhead
Sarepta Therapeutics is paying Arrowhead Pharmaceuticals $500 million in cash, plus a $325 million equity investment, for worldwide licensing rights to seven programs—four clinical and three preclinical—in addition to a discovery partnership with six targets.
Arrowhead Pharmaceuticals' stock rallied 17% due to significant pipeline developments and strategic partnerships. Learn more ...
Stocktwits on MSN15h
Arrowhead, Sarepta Stocks Rise Despite Price-Target Cuts Post $1B Licensing Deal: Retail Buzz Strong($ARWR) and Sarepta Therapeutics Inc. ($SRPT) climbed on Wednesday despite Wall Street trimming price targets after the ...
12hon MSN
The Chiefs are welcoming the Raiders back to Arrowhead Stadium on Friday after a stunning loss to their longtime and bitter ...
Fans attending the Chiefs Black Friday game to get special "Holiday Touchdown: A Chiefs Love Story" branded pennant.
While on set of “Holiday Touchdown,” Hallmark and the Kansas City Chiefs’ football romance, TODAY learned from those behind ...
Head Coach Antonio Pierce discusses finding a balance on offense, defensive end Tyree Wilson and facing the Kansas City ...
Sarepta Therapeutics said it will pay Arrowhead Pharmaceuticals $500 million in cash for a series of experimental RNA-based ...
A broad licensing and research alliance will hand Sarepta four clinical-stage candidates, while Arrowhead receives $500 ...
Colorado is bringing an "iced out" look to Arrowhead Stadium this weekend for their critical Big 12 showdown against Kansas.
After Sarepta (SRPT) announced a global licensing and collaboration agreement with Arrowhead (ARWR) that adds four clinical-stage siRNA assets ...
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) shares are trading higher Tuesday after the company announced a global ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback